BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

17903

500488

ABBOTINDIA

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

ABBOTT INDIA LIMITED performance

Today’s low

Today’s high

₹ 29700.00 ₹ 30100.00
₹ 29985.00

52 week low

52 week high

₹ 25325.00 ₹ 31898.95
₹ 29985.00

Open Price

₹ 30000.00

Prev. Close

₹ 30100.00

Volume (Shares)

3754.00

Total traded value

₹ 1125.63

Upper Circuit

₹ 36120.00

Lower Circuit

₹ 24080.00

info

ABBOTT INDIA LIMITED Share Price Update

As of the latest trading session, ABBOTT INDIA LIMITED share price is currently at ₹ 29985, which is down by ₹ -115.00 from its previous closing. Today, the stock has fluctuated between ₹ 29700.00 and ₹ 30100.00. Over the past year, ABBOTT INDIA LIMITED has achieved a return of 14.49 %. In the last month alone, the return has been -0.71 %. Read More...

ABBOTT INDIA LIMITED fundamentals


  • Market cap (Cr)

    63,718.10

  • P/E Ratio (TTM)

    47.92

  • Beta

    0.45

  • Book Value / share

    1,656.99

  • Return on equity

    34.88%

  • EPS (TTM)

    627.98

  • Dividend yield

    1.36%

  • Net profit/quarter (Cr)

    360.78

info icon alternate text
  • Market cap (Cr)

    63,488.50

  • P/E Ratio (TTM)

    47.92

  • Beta

    0.42

  • Book Value / share

    1,656.99

  • Return on equity

    34.88%

  • EPS (TTM)

    627.98

  • Dividend yield

    1.36%

  • Net profit/quarter (Cr)

    360.78

info icon alternate text

ABBOTT INDIA LIMITED Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 1614.28
Operating Expense 1198.44
Net Profit 360.78
Net Profit Margin (%) 22.34
Earnings Per Share (EPS) 169.78
EBITDA 507.84
Effective Tax Rate (%) 26.00
Particulars SEP 2024 (Values in Cr)
Revenue 1632.67
Operating Expense 1213.72
Net Profit 358.61
Net Profit Margin (%) 21.96
Earnings Per Share (EPS) 168.76
EBITDA 499.44
Effective Tax Rate (%) 25.20
Particulars JUN 2024 (Values in Cr)
Revenue 1557.61
Operating Expense 1187.72
Net Profit 328.01
Net Profit Margin (%) 21.05
Earnings Per Share (EPS) 154.36
EBITDA 458.34
Effective Tax Rate (%) 24.97
Particulars MAR 2024 (Values in Cr)
Revenue 1438.63
Operating Expense 1130.10
Net Profit 287.06
Net Profit Margin (%) 19.95
Earnings Per Share (EPS) 135.09
EBITDA 410.68
Effective Tax Rate (%) 26.33
Particulars DEC 2023 (Values in Cr)
Revenue 1437.14
Operating Expense 1070.59
Net Profit 310.98
Net Profit Margin (%) 21.63
Earnings Per Share (EPS) 146.34
EBITDA 443.30
Effective Tax Rate (%) 26.33
Particulars MAR 2024 (Values in Cr)
Revenue 5848.91
Operating Expense 4479.42
Net Profit 1201.22
Net Profit Margin (%) 20.53
Earnings Per Share (EPS) 565.28
EBITDA 1701.37
Effective Tax Rate (%) 25.74
Particulars MAR 2023 (Values in Cr)
Revenue 5348.73
Operating Expense 4229.05
Net Profit 949.41
Net Profit Margin (%) 17.75
Earnings Per Share (EPS) 446.78
EBITDA 1359.78
Effective Tax Rate (%) 25.46
Particulars MAR 2022 (Values in Cr)
Revenue 4913.32
Operating Expense 3916.75
Net Profit 798.70
Net Profit Margin (%) 16.25
Earnings Per Share (EPS) 375.86
EBITDA 1164.92
Effective Tax Rate (%) 26.02
Particulars MAR 2021 (Values in Cr)
Revenue 4310.02
Operating Expense 3464.97
Net Profit 690.69
Net Profit Margin (%) 16.02
Earnings Per Share (EPS) 325.04
EBITDA 1002.36
Effective Tax Rate (%) 25.40
Particulars MAR 2020 (Values in Cr)
Revenue 4093.14
Operating Expense 3404.83
Net Profit 592.93
Net Profit Margin (%) 14.48
Earnings Per Share (EPS) 279.04
EBITDA 870.84
Effective Tax Rate (%) 26.13
Particulars (Values in Cr)
Book Value / Share 106.54
ROE % 37.86
ROCE % 54.90
Total Debt to Total Equity 0.02
EBITDA Margin 21.29
Particulars (Values in Cr)
Book Value / Share 81.86
ROE % 40.85
ROCE % 53.59
Total Debt to Total Equity 0.02
EBITDA Margin 19.09
Particulars MAR 2024 (Values in Cr)
Book Value / Share 1740.65
ROE % 34.88
ROCE % 44.71
Total Debt to Total Equity 0.03
EBITDA Margin 28.96
Particulars MAR 2023 (Values in Cr)
Book Value / Share 1500.49
ROE % 31.60
ROCE % 39.94
Total Debt to Total Equity 0.04
EBITDA Margin 25.28
Particulars MAR 2022 (Values in Cr)
Book Value / Share 1326.96
ROE % 29.46
ROCE % 37.20
Total Debt to Total Equity 0.06
EBITDA Margin 23.62
Particulars MAR 2021 (Values in Cr)
Book Value / Share 1224.55
ROE % 27.44
ROCE % 34.11
Total Debt to Total Equity 0.07
EBITDA Margin 23.26
Particulars MAR 2020 (Values in Cr)
Book Value / Share 1144.33
ROE % 26.71
ROCE % 33.98
Total Debt to Total Equity 0.04
EBITDA Margin 21.28
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 2134.49
Total Assets 5193.49
Total Liabilities 5193.49
Total Equity 3698.89
Share Outstanding 21249302
Price to Book Ratio 15.48
Return on Assets (%) 23.12
Return on Capital (%) 32.48
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1937.06
Total Assets 4555.51
Total Liabilities 4555.51
Total Equity 3188.54
Share Outstanding 21249302
Price to Book Ratio 14.72
Return on Assets (%) 20.84
Return on Capital (%) 29.78
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2749.22
Total Assets 4224.12
Total Liabilities 4224.12
Total Equity 2819.79
Share Outstanding 21249302
Price to Book Ratio 13.34
Return on Assets (%) 18.90
Return on Capital (%) 28.32
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 2409.04
Total Assets 3840.45
Total Liabilities 3840.45
Total Equity 2602.16
Share Outstanding 21249302
Price to Book Ratio 12.24
Return on Assets (%) 17.98
Return on Capital (%) 26.54
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 2197.38
Total Assets 3546.85
Total Liabilities 3546.85
Total Equity 2431.70
Share Outstanding 21249302
Price to Book Ratio 13.51
Return on Assets (%) 16.71
Return on Capital (%) 24.38
Particulars MAR 2024 (Values in Cr)
Net Income 1617.75
Cash from Operations 1617.28
Cash from Investing -416.03
Cash from Financing -744.71
Net change in Cash 52.07
Free Cash Flow 1665.61
Particulars MAR 2023 (Values in Cr)
Net Income 1273.82
Cash from Operations 1234.25
Cash from Investing -147.71
Cash from Financing -638.72
Net change in Cash 106.96
Free Cash Flow 1268.36
Particulars MAR 2022 (Values in Cr)
Net Income 1079.73
Cash from Operations 1236.65
Cash from Investing -395.84
Cash from Financing -637.38
Net change in Cash -85.56
Free Cash Flow 1280.72
Particulars MAR 2021 (Values in Cr)
Net Income 925.95
Cash from Operations 962.20
Cash from Investing -71.82
Cash from Financing -581.79
Net change in Cash 73.13
Free Cash Flow 985.51
Particulars MAR 2020 (Values in Cr)
Net Income 802.70
Cash from Operations 855.30
Cash from Investing -401.21
Cash from Financing -216.79
Net change in Cash 8.13
Free Cash Flow 871.04
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 37.10 19.95 2.02 284.31 34.11 / 77.70
BLISS GVS PHARMA LTD 122.65 16.07 1.27 1292.37 92.25 / 184.95
CIPLA LTD 1541.00 24.94 4.38 124457.39 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 272.25 22.56 2.76 801.26 145.00 / 449.00
GLAXOSMITHKLINE PHARMA LT 2904.45 57.61 29.41 49203.14 1924.30 / 3147.45
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 37.10 22.35 6.30 284.31 34.11 / 77.70
AMRUTAJAN HEALTH LTD 679.10 39.81 6.59 1963.32 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8795.90 131.18 32.36 21989.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 122.65 15.93 1.26 1292.37 92.25 / 184.95

ABBOTT INDIA LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
29985.00 -0.38 redarrow
red-green-graph indicator
11 Bearish
5 Bullish
  • 5 Days 30072.20
  • 26 Days 30112.70
  • 10 Days 30149.00
  • 50 Days 29852.00
  • 12 Days 30156.60
  • 100 Days 29398.10
  • 20 Days 30149.10
  • 200 Days 28668.70
29725.00 PIVOT

First Support

29505.00

First Resistance

30000.00

Second Support

29230.00

Second Resistance

30220.00

Third Support

29010.00

Third Resistance

30495.00

RSI

49.95

ADX

16.08

MACD

43.86

Williams % R

-33.33

Commodity Channel Index (CCI)

-19.07

Date

2025-04-29

Week

2496.00

Same Day

2568.00

Month

2972.00

1 Year

0.46

3 Year

0.42

Over 1 Month

-0.71%

down

Over 1 Year

14.49%

down

Over 3 Months

18.03%

down

Over 3 Years

20.78%

down

Over 6 Months

5.71%

down

Over 5 Years

10.84%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

ABBOTT INDIA LIMITED shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
15.93%
Promoter Holdings
74.98%
FII
0.16%
DII
8.91%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Abbott Capital India Limited 1.0719097E7 (50.44%) Shareholding of Promoter and Promoter Group
Abbott Healthcare Products Limited 3744951.0 (17.62%) Shareholding of Promoter and Promoter Group
British Colloids Limited 1470000.0 (6.92%) Shareholding of Promoter and Promoter Group
Sbi Retirement Benefit Fund 577616.0 (2.72%) Public Shareholding
Canara Robeco Mutual Fund 243520.0 (1.15%) Public Shareholding

News

Left Arrow
Right Arrow

ABBOTT INDIA LIMITED corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
21 Jul 2023 180.0 Final 21 Jul 2023 Equity shares
21 Jul 2023 145.0 Special 21 Jul 2023 Equity shares
02 Aug 2022 145.0 Final 04 Aug 2022 Equity shares
02 Aug 2022 130.0 Special 04 Aug 2022 Equity shares
19 Jul 2021 120.0 Final 21 Jul 2021 Equity shares
19 Jul 2021 155.0 Special 21 Jul 2021 Equity shares
28 Aug 2020 107.0 Final 01 Sep 2020 Equity shares
28 Aug 2020 143.0 Special 01 Sep 2020 Equity shares
13 Aug 2019 50.0 Final 16 Aug 2019 Equity shares
13 Aug 2019 15.0 Special 16 Aug 2019 Equity shares
10 Jul 2018 50.0 Final 12 Jul 2018 Equity shares
10 Jul 2018 5.0 Special 12 Jul 2018 Equity shares
10 Jul 2017 40.0 Final 12 Jul 2017 Equity shares
08 Jul 2016 35.0 Final 12 Jul 2016 Equity shares
22 Jul 2015 31.0 Final 24 Jul 2015 Equity shares
23 Jul 2014 23.0 Final 25 Jul 2014 Equity shares
16 Apr 2013 17.0 Final 18 Apr 2013 Equity shares
04 May 2012 17.0 Final 08 May 2012 Equity shares
19 Apr 2011 17.0 Final 21 Apr 2011 Equity shares
03 Mar 2010 17.0 Final 05 Mar 2010 Equity shares
09 Mar 2009 14.0 Final 13 Mar 2009 Equity shares
28 Mar 2008 17.5 Final 01 Apr 2008 Equity shares
05 Apr 2007 0.0 Final 10 Apr 2007 Equity shares
Ex-Date Ex-Bonus Ratio
11 Sep 1998 17 Aug 1998 1:1
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
19 Jul 2024 410.0 Final 19 Jul 2024 Equity shares
21 Jul 2023 180.0 Final 21 Jul 2023 Equity shares
21 Jul 2023 145.0 Special 21 Jul 2023 Equity shares
02 Aug 2022 145.0 Final 04 Aug 2022 Equity shares
02 Aug 2022 130.0 Special 04 Aug 2022 Equity shares
19 Jul 2021 120.0 Final 21 Jul 2021 Equity shares
19 Jul 2021 155.0 Special 21 Jul 2021 Equity shares
28 Aug 2020 107.0 Final 01 Sep 2020 Equity shares
28 Aug 2020 143.0 Special 01 Sep 2020 Equity shares
13 Aug 2019 50.0 Final 16 Aug 2019 Equity shares
13 Aug 2019 15.0 Special 16 Aug 2019 Equity shares
10 Jul 2018 50.0 Final 12 Jul 2018 Equity shares
10 Jul 2018 5.0 Special 12 Jul 2018 Equity shares
10 Jul 2017 40.0 Final 12 Jul 2017 Equity shares
08 Jul 2016 35.0 Final 12 Jul 2016 Equity shares
22 Jul 2015 31.0 Final 24 Jul 2015 Equity shares
23 Jul 2014 23.0 Final 25 Jul 2014 Equity shares
16 Apr 2013 17.0 Final 18 Apr 2013 Equity shares
04 May 2012 17.0 Final 08 May 2012 Equity shares
19 Apr 2011 17.0 Final 21 Apr 2011 Equity shares
03 Mar 2010 17.0 Final 05 Mar 2010 Equity shares
09 Mar 2009 14.0 Final 13 Mar 2009 Equity shares
28 Mar 2008 17.5 Final 01 Apr 2008 Equity shares
05 Apr 2007 0.0 Final 10 Apr 2007 Equity shares
Ex-Date Ex-Bonus Ratio
11 Sep 1998 17 Aug 1998 1:1
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

ABBOTT INDIA LIMITED Share Price

Abbott India Ltd. is one of the leading multinational pharmaceutical companies in India and operates with an owned manufacturing facility in Goa and various independent contract/third party manufacturers based across the country. The Company sells its products through independent distributors primarily within India. It provides products and solutions across various therapeutic areas such as Women's Health, Gastroenterology, Central Nervous System, Metabolics, Multi-Specialty, Vaccines, Consumer Health, etc. Its global products include Brufen, Prothiaden, Thyronorm and Leptos.

The company has four divisions. The Primary Care division markets products in the areas of pain management and gastroenterology. The Specialty Care-Methabolics and Urology division provides solutions in the areas of thyroid, obesity, diabetes and benign prostatic hyperplasia. The Specialty Care-Neuroscience division has a varied portfolio with specialty products in neurology and psychiatric segments. Hospital Care offers products in the field of anesthesiology and neonatology, such as Forane, Sevorane and Survanta.

Abbott India Ltd was originally incorporated on August 22, 1944 as Boots Pure Drug Company (India) Ltd. The company name was changed to The Boots Company (India) Ltd on November 1, 1971, thereafter to Boots Pharmaceuticals Ltd on January 1, 1991. In October 31, 1995 the name was changed to Knoll Pharmaceuticals Ltd, and in July 1, 2002, they got their present name Abbott India Ltd.

In the year 2002, the company sold their Jejuri Undertakings together with assets and liabilities as a going concern. In the year 2003, the company's wholly owned subsidiary company, Lenbrook Pharmaceuticals Ltd was amalgamated with the company.

In the year 2004, the company started the production of Capsules with the capacity of 27 Millions Nos. In the year 2005, they further increased the capacity to 56 Million Nos. Also, they started a new project of producing Nutritional Products with the installed capacity of 600 Tonnes.

In the year 2006, the company increased the production capacity of Tablets by 236 Million Nos to 686 Million Nos. In the year 2008, they further increased the production capacity of Tablets by 769 million Nos to 1455 million Nos. They launched Digene Total, buffered pantoprazole tablet for quick and sustained antacid action and Brugel a novel formulation for sprains and strains. Also, they launched Thyronorm 150, Digene Sugar Free Tablet and Gel during the year.

The Buy-Back Committee of the Board of Directors of Abbott India at its meeting held on 9 July 2008 approved buy-back of 7.97 lakh fully paid-up equity shares of the company via the tender offer method, at a price of Rs 630 per share.

The Board of Directors of Abbott India Ltd. and Solvay Pharma India Ltd. at their respective meetings held on 24 November 2010 unanimously approved the draft scheme for the amalgamation of Solvay Pharma India into Abbott India under sections 391 to 394 of the Companies Act 1956. The swap ratio for the merger recommended is 2:3. In other words, every two shares of the Solvay Pharma India Ltd. will entitle their holder to three shares of Abbott India Ltd.

On 17 May 2011, Abbott Capital India Limited sold 2.24 lakh shares out of its total holding of 94.28 lakh shares in Abbott India Limited by way of an on market transaction. As a consequence, the promoter shareholding in Abbott India Limited after the merger of Solvay Pharma India Limited into Abbott India Limited will be 74.98%. Therefore, the listing of shares issued pursuant to the share exchange ratio in the merger will not result in the public shareholding in Abbott India Limited falling below 25%, as required under Clause 40A of the Listing Agreement.

On 7 September 2011, Abbott India completed the allotment of 75.74 lakh equity shares to the shareholders of Solvay Pharma India Ltd in the ratio of 2:3, in terms of the Scheme of Amalgamation of Solvay Pharma India Ltd with Abbott India.

The Board of Directors of Abbott India at its meeting held on 3 June 2013 decided to defer the proposal received by the company for the sale and transfer of, or other appropriate restructuring of, the proprietary pharmaceuticals division (PPD) of the company. Abbott Laboratories, the ultimate parent corporation of Abbott India, has separated into two publicly traded companies - one in diversified medical products and the other in research-based pharmaceuticals. The parent company for the research-based pharmaceutical companies is AbbVie Inc., a Delaware corporation. For the year ended 31 December 2012, the PPD business accounted 4.73% of net sales of Abbott India.

With effect from the financial year ended 31 March 2014, the company changed its accounting year from year ended 31 December 31 to year ended 31 March. Accordingly, financial statements are prepared for 15 months' period from 1 January 2013 to 31 March 2014. The Drug Price Control Order, 2013 has brought several of the company's products under price control. The company reduced the prices of the products covered under the new DPCO, which resulted in an adverse impact of Rs 11,00.00 Lakhs on Sales and Profits of the company during the period 2013-14. During the period, the company sold residential properties which yielded a profit of approximately Rs 12,20.00 Lakhs.

During the period under review, the company's General Care therapeutic segment achieved a turnaround, moving from a negative growth of 4.6% to positive double digit growth of 13.5%. This was possible through stellar performance in key brands: Betonin, Kinetone, Digecaine and Digene growing faster than their participated market.

For the central nervous system (CNS) therapeutic area, the persistent emphasis on a continuum of care approach made the company's Zolfresh brand number 2 brand through the period 2013-14.

During the financial year ended 31 March 2015, the company's General Care Division launched a new product Arachitol Nano.

During the financial year ended 31 March 2016, Abbott India launched 17 new products in various therapy segments, which together contributed 1.9% of the Net Sales of the company. During the year under review, the company entered into a licensing arrangement with Bharat Biotech India Limited to market vaccines in immunology segment.

During the financial year ended 31 March 2017, Abbott India launched 10 new products in various therapy segments, which contributed 0.7% of the sales of the company.

Abbott India formed new Business Unit GI Advance in January 2018 to build new products on a build, operate, transfer model.

During the financial year ended 31 March 2018, the company Women's Health & Gastrointestine division launched 2 new products - Cystofert (Polycystic Ovary Syndrome) and Letrolife (Ovulation). The Gastroenterology division launched 4 new products - Duphalac Bulk (Gut Health), Duphapro (Constipation), Udiliv 450 (NAFLD) and Duphalac Lemon Flavor (Laxative). The GI Prospera division launched 3 new products - Velpaclear (Hepatitis C), Antoxipan (Pain Management in chronic pancreatitis) and Heptral T (ALD/NAFLD).

During the year under review, the Metabolics business unit launched one new product - Combinorm (Probiotic - Bacterial Vaginosis). The Central Nervous System business unit launched 2 new products - Inderal 20 (Migrane) and Cerebion (Stroke/Brain Injury).

The Consumer Care Division launched 5 new products - Rashfree Natural Cream (Diaper Rash Cream), Digene Paan Flavour (Antacid), Digene Pudina Pearls (Digestive), Cremaffin Fresh (Laxative) and Brufen Active (Pain Relief Ointment).

During the year under review, Abbott India received approvals to conduct phase 3 studies in adults/elderly and pediatrics in parallel for its Influvac, Quadrivalent Vaccine (QIV) Program.

During the year, Abbott India granted a loan of Rs 200 crore to Alere Medical Private Limited, India (a Related Party as per the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015) for a period of six months on December 26, 2017, at an interest rate of 10% per annum pursuant to the provisions of Section 186 of the Companies Act, 2013 and Rules framed thereunder, to pay off its existing inter-company trade liability. The said loan is guaranteed by Abbott Laboratories, USA i.e. the ultimate holding company.

During the FY2018,the company executed 23 new studies,published 14 publications in major indexed journals and made 7 international congress presentations.

During the FY2019,the company executed 25 new studies, published 45 articles in major indexed journals, with 6 international presentations.

The company has been awarded THE MOST INNOVATIVE MNC OF THE YEAR 2019 at the 12th Pharma Leaders Award.

During the FY2020, the company executed 12 new studies, published 16 articles in major indexed journals, along with making four international presentations.

During the FY2021, there was a innovation in Brufen Coating formula which led to 50% increase in coating Installed capacity in 2 shifts from 675 mio tabs to 1,012 mio tabs without any capex. Increase in installed capacity will help site to produce all Brufen SKU's in-house as well as scope for internalization of new coated product.

During the year 2020-21, the company executed 8 new studies, published 8 articles in major indexed journals. All the studies were conducted in compliance with Good Clinical Practice (GCP) and regulatory requirements.

During the year 2022, company continued portfolio expansion and launched 10 new differentiated products in the market to meet increasing healthcare needs. It increased presence in high growth therapy areas such as adult vaccination and new sub-therapies like menopause. It strengthened the multi-channel engagement and leveraged technology to engage with patients and doctors for better health outcomes. It empowered patients across multiple therapies for vertigo, epilepsy, influenza, Vitamin D, insomnia with multi-media awareness campaigns. It led strategic partnerships with key associations to advance therapy shaping standards. It lead differentiated Healthcare Professionals (HCPs) facing initiatives to drive therapy leadership in key therapeutic areas. It brought synergy in patient care efforts through launch of a Center of Excellence.

During the year 2022, three new products viz. Riligol (post partum haemorrhage), Preservgest (pregnancy maintenance) and Femoston 2/10 (postmenopausal symptoms) were launched. It further launched two unique products, PreservGest, which is a micronized progesterone, and Arachitol Gummies, Vitamin D and Calcium Gummies in the multi-speciality medicine portfolio. Its strong presence in Gastrointestinal space was further strengthened with the success of Digeraft. In this portfolio, it also launched a unique pre+probiotic, Florachamp, to help restore gut balance.

During the year 2022, Florachamp (i.e., probiotic for irritable bowel syndrome) was launched for Gastroenterology therapeutic area. To expand the Multi-Specialty portfolio, the Company launched a new brand Arachitol Gummies, an innovative orange flavored FSSAI approved to fulfill daily requirements of Vitamin D and Calcium. It launched Havshield, vaccine for immunization against Hepatitis-A in line with Vaccines portfolio. It also launched In-Home-Vaccination' and FLUVaccine-Reminder' service to improve the vaccine compliance. The Company also partnered with over 12 medical associations to drive capability building in various therapeutic areas. It used digital technologies to reach out to doctors and provide therapy updates to them.

During the year 2023, the Company launched Brufen P (Ibuprofen + Paracetamol) . Focusing on the need gap of hypothyroidism treatment, it launched Liothyronine (T3) molecule - Linorma T3 tablet. New products like Femoston Mini (post-menopausal symptoms), Solfe extra tablet (iron deficiency anemia) and Cetropro vial (IVF) were launched on Women's health portfolio during the year 2023. Cortirowa OD (ulcerative colitis), Digeraft XT (gastroesophageal reflux), Digeraft Plus (gastroesophageal reflux) and Cremagel-L (anal fissures) were launched.

Parent organization MNC Associate - Abbott
NSE symbol ABBOTINDIA
Founded 1944
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Abbott India Ltd?

Answer Field

The share price of Abbott India Ltd for NSE is ₹ 29985 and for BSE is ₹ 29845.

What is the Market Cap of Abbott India Ltd?

Answer Field

The market cap of Abbott India Ltd for NSE is ₹ 6,37,18.10 Cr. and for BSE is ₹ 0.0 Cr. as of now.

What is the 52 Week High and Low of Abbott India Ltd?

Answer Field

The 52 Week High and Low of Abbott India Ltd for NSE is ₹ 31898.95 and ₹ 25325.00 and for BSE is ₹ 31900.00 and ₹ 25260.20.

How to Buy Abbott India Ltd share?

Answer Field

You can trade in Abbott India Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Abbott India Ltd?

Answer Field

The 1 year returns on the stock has been 14.49%.

What is the Current Share Price of Abbott India Ltd?

Answer Field

Abbott India Ltd share price is for NSE ₹ 29985 & for BSE ₹ 29845 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Abbott India Ltd Share?

Answer Field

The market cap of Abbott India Ltd for NSE ₹ 6,37,18.10 & for BSE ₹ 0.0 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Abbott India Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Abbott India Ltd share is 47.92.

What is the PB ratio of Abbott India Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Abbott India Ltd share is 1656.99.

How to Buy Abbott India Ltd Share?

Answer Field

You can trade in Abbott India Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Abbott India Ltd Share on Bajaj Broking App?

Answer Field

To buy Abbott India Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Abbott India Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|